REGENTIS BIOMATERIALS LTD.

RGNTdata completeness 75%3 fiscal years on file

Data notes: no data for concept 'revenue'; no data for concept 'capex'; no data for concept 'incomeTaxExpense'

The thesis, from the filings

REGENTIS BIOMATERIALS LTD. earns about -288% on equity, but has diluted owners by 227% over 3 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own

Figure	FY 2023	FY 2024	FY 2025
Revenue	—	—	—
Net income	−$4.13M¹	$4.8M¹	−$13.6M¹
Operating cash flow	−$1.22M²	−$641,000²	−$1.38M²
Capital expenditure	—	—	—
Free cash flow (derived)	—	—	—
Total debt	$210,000³	$573,000³	$1.2M³
Cash & equivalents	—	—	$7.38M⁴
Diluted shares	173,508	2.8M	566,744

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

$83.71

your share of equity

Profit it earned you last year

−$240.81

Free cash flow it threw off

—

Debt you’d be carrying

$21.12

10 shares is a claim on $83.71 of net worth that earned you −$240.81 last year, against $21.12 of debt.

iii. Is this a good business?

Moat signal · return on equity

-288% avg · 3y

FY23 —FY24 —FY25 -288%

It earned an average -288% on equity over 3 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →

Management signal · capital allocation

+227% shares · 3y

Share count is up 227% over 3 years — owners have been diluted. Worth asking what they got for it. Total debt has risen 470% over the same window.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts

20-F/A · period ending 2023-12-31 · accession 0001213900-26-021722 (NetIncomeLoss)
20-F/A · period ending 2023-12-31 · accession 0001213900-26-021722 (NetCashProvidedByUsedInOperatingActivities)
20-F/A · period ending 2023-12-31 · accession 0001213900-26-021722 (ShortTermBorrowings)
20-F/A · period ending 2025-12-31 · accession 0001213900-26-021722 (CashAndCashEquivalentsAtCarryingValue)